Intervention not reported
Placebo · patients with moderate to severe eczema
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Findings
What do systematic reviews say?
265 questions · 283 findings · 18 reviews · Skin
No studies found 59 · 20.8%GRADE not reported 20 · 7.1%Very low 45 · 15.9%Low 58 · 20.5%Moderate 64 · 22.6%High 37 · 13.1%
Intervention not reported
Total studies: 17 RCTsTotal participants: 3972 · patients with moderate to severe eczema
1 finding from 1 review
- no estimate extracted17 studies · 3972 participantsGRADE not reported
Intervention not reported
QAW039 (1 RCT; 76 participants) · patients with moderate to severe eczema
The intervention probably leads to lower QAW039 (1 RCT; 76 participants) (moderate certainty).
1 finding from 1 review
- RR 0.09 [0.01, 0.76]1 study · 39 participantsModerate
Intervention not reported
Dupilumab (9 RCTs; 1663 participants) · patients with moderate to severe eczema
The intervention may leads to lower dupilumab (9 RCTs; 1663 participants) (low certainty).
1 finding from 1 review
- RR 0.37 [0.23, 0.59]9 studies · 1663 participantsLow
Intervention not reported
Timapiprant (1 RCT; 70 participants) · patients with moderate to severe eczema
The intervention showed no clear difference in timapiprant (1 RCT; 70 participants) (low certainty).
1 finding from 1 review
- RR 0.34 [0.07, 1.62]1 study · 70 participantsLow
Anti‐PD1 monoclonal antibodies vs chemotherapy alone
Overall survival† · people with cutaneous melanoma
Anti‐PD1 monoclonal antibodies leads to lower overall survival† compared with chemotherapy (high certainty).
1 finding from 1 review
- HR 0.42 [0.37, 0.48]418 participantsHigh
Anti‐CTLA4 monoclonal antibodies plus chemotherapy vs chemotherapy alone
Progression‐free survival · people with cutaneous melanoma
Anti‐CTLA4 monoclonal antibodies plus chemotherapy probably leads to lower progression‐free survival† compared with chemotherapy (moderate certainty).
1 finding from 1 review
- HR 0.76 [0.63, 0.92]502 participantsModerate
Anti‐CTLA4 monoclonal antibodies plus chemotherapy vs chemotherapy alone
Tumour response · people with cutaneous melanoma
Anti‐CTLA4 monoclonal antibodies plus chemotherapy showed no clear difference in tumour response compared with chemotherapy (moderate certainty).
1 finding from 1 review
- RR 1.28 [0.92, 1.77]1157 participantsModerate
Anti‐CTLA4 monoclonal antibodies plus chemotherapy vs chemotherapy alone
Toxicity (≥ G3) · people with cutaneous melanoma
Anti‐CTLA4 monoclonal antibodies plus chemotherapy probably leads to higher toxicity (≥ G3) compared with chemotherapy (moderate certainty).
1 finding from 1 review
- RR 1.69 [1.19, 2.42]1142 participantsModerate
Anti‐CTLA4 monoclonal antibodies with vs without anti‐PD1 monoclonal antibodies
Overall survival · people with cutaneous melanoma
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Anti‐CTLA4 monoclonal antibodies with vs without anti‐PD1 monoclonal antibodies
Progression‐free survival · people with cutaneous melanoma
Anti‐CTLA4 monoclonal antibodies with leads to lower progression‐free survival† compared with without anti‐PD1 monoclonal antibodies (high certainty).
1 finding from 1 review
- HR 0.4 [0.35, 0.46]738 participantsHigh
Anti‐CTLA4 monoclonal antibodies with vs without anti‐PD1 monoclonal antibodies
Tumour response · people with cutaneous melanoma
Anti‐CTLA4 monoclonal antibodies with leads to higher tumour response compared with without anti‐PD1 monoclonal antibodies (high certainty).
1 finding from 1 review
- RR 3.5 [2.07, 5.92]738 participantsHigh
Anti‐CTLA4 monoclonal antibodies with vs without anti‐PD1 monoclonal antibodies
Toxicity (≥ G3) · people with cutaneous melanoma
Anti‐CTLA4 monoclonal antibodies with showed no clear difference in toxicity (≥ G3) compared with without anti‐PD1 monoclonal antibodies (low certainty).
1 finding from 1 review
- RR 1.57 [0.85, 2.92]764 participantsLow
BRAF inhibitors vs chemotherapy alone
Overall survival† · people with cutaneous melanoma
BRAF inhibitors leads to lower overall survival† compared with chemotherapy (high certainty).
1 finding from 1 review
- HR 0.4 [0.28, 0.57]925 participantsHigh
BRAF inhibitors vs chemotherapy alone
Progression‐free survival · people with cutaneous melanoma
BRAF inhibitors leads to lower progression‐free survival† compared with chemotherapy (high certainty).
1 finding from 1 review
- HR 0.27 [0.21, 0.34]925 participantsHigh
BRAF inhibitors vs chemotherapy alone
Tumour response · people with cutaneous melanoma
BRAF inhibitors leads to higher tumour response compared with chemotherapy (high certainty).
1 finding from 1 review
- RR 6.78 [4.84, 9.49]925 participantsHigh
Anti‐PD1 monoclonal antibodies vs chemotherapy alone
Progression‐free survival · people with cutaneous melanoma
Anti‐PD1 monoclonal antibodies probably leads to lower progression‐free survival† compared with chemotherapy (moderate certainty).
1 finding from 1 review
- HR 0.49 [0.39, 0.61]957 participantsModerate
BRAF inhibitors vs chemotherapy alone
Toxicity (≥ G3) · people with cutaneous melanoma
BRAF inhibitors showed no clear difference in toxicity (≥ G3) compared with chemotherapy (low certainty).
1 finding from 1 review
- RR 1.27 [0.48, 3.33]408 participantsLow
MEK inhibitors vs chemotherapy alone
Overall survival† · people with cutaneous melanoma
MEK inhibitors showed no clear difference in overall survival† compared with chemotherapy (low certainty).
1 finding from 1 review
- HR 0.85 [0.58, 1.25]496 participantsLow
MEK inhibitors vs chemotherapy alone
Progression‐free survival · people with cutaneous melanoma
MEK inhibitors probably leads to lower progression‐free survival† compared with chemotherapy (moderate certainty).
1 finding from 1 review
- HR 0.58 [0.42, 0.8]496 participantsModerate